Bleakley Financial Group LLC Invests $671,000 in Haleon PLC Sponsored ADR $HLN

Bleakley Financial Group LLC acquired a new stake in shares of Haleon PLC Sponsored ADR (NYSE:HLN) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 64,712 shares of the company’s stock, valued at approximately $671,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Allspring Global Investments Holdings LLC increased its holdings in Haleon by 6.1% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 30,223 shares of the company’s stock worth $306,000 after acquiring an additional 1,749 shares during the period. Acadian Asset Management LLC bought a new stake in Haleon during the 1st quarter worth approximately $1,767,000. Arlington Partners LLC bought a new stake in Haleon during the 2nd quarter worth approximately $2,315,000. Oppenheimer & Co. Inc. increased its holdings in Haleon by 11.2% during the 1st quarter. Oppenheimer & Co. Inc. now owns 25,362 shares of the company’s stock worth $261,000 after acquiring an additional 2,564 shares during the period. Finally, Concurrent Investment Advisors LLC increased its holdings in Haleon by 32.9% during the 1st quarter. Concurrent Investment Advisors LLC now owns 16,363 shares of the company’s stock worth $168,000 after acquiring an additional 4,055 shares during the period. Institutional investors own 6.67% of the company’s stock.

Analyst Upgrades and Downgrades

HLN has been the topic of a number of analyst reports. The Goldman Sachs Group raised shares of Haleon from a “neutral” rating to a “buy” rating in a report on Wednesday, September 10th. Wall Street Zen lowered shares of Haleon from a “buy” rating to a “hold” rating in a report on Saturday, July 12th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Haleon in a report on Saturday. Finally, Barclays lowered shares of Haleon from an “overweight” rating to an “equal weight” rating in a report on Tuesday, September 16th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $12.33.

Haleon Price Performance

Shares of Haleon stock opened at $9.25 on Monday. Haleon PLC Sponsored ADR has a 52-week low of $8.71 and a 52-week high of $11.42. The stock has a market capitalization of $41.17 billion, a price-to-earnings ratio of 23.71, a price-to-earnings-growth ratio of 2.70 and a beta of 0.20. The company has a fifty day moving average of $9.38 and a 200-day moving average of $9.98. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.63 and a current ratio of 0.87.

Haleon Increases Dividend

The firm also recently disclosed a semi-annual dividend, which was paid on Thursday, September 18th. Stockholders of record on Friday, August 15th were paid a $0.0555 dividend. This is a positive change from Haleon’s previous semi-annual dividend of $0.05. The ex-dividend date of this dividend was Friday, August 15th. This represents a dividend yield of 190.0%. Haleon’s dividend payout ratio is currently 28.21%.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.